REMARKS

Reconsideration is requested.

The specification has been corrected according to the Examiner's comment on page 2 of the Office Action dated May 24, 2004, with regard to the cross-reference to the parent application. The Examiner's comment is appreciated.

Claims 1-28 have been canceled, without prejudice. Claims 29-55 have been added and are pending. Claims 29, 30 and 32-55 are similar to now-canceled claims 1-26, respectively. Claim 31 has been added as an intermediate claim between nowcanceled claims 2 and 3. Claim 29 is similar to claim 1 with recitations additionally included as originally-disclosed, for example, at page 4, lines 3-4, page 4, lines 16-19, page 5, lines 5-6 and page 5, 15-16. New claim 31 finds support, for example, on page 5, lines 26-27. New claim 38, as compared with now-canceled claim 9, includes an additional compound as originally-disclosed on page 8, lines 3-4 of the specification. Claim 40 is similar to now-canceled claim 11 with the additional recitation of the compound disclosed at page 8, lines 16-17. Claim 43 is similar to now-canceled claim 14 however new claim 43 is depended on new claim 29 and the proviso has been revised to be consistent with new claim 29, from which it depends. New claim 49 is similar to new claim 29 in the recitation of the compounds. Moreover, new claim 49, which is similar to now-canceled claim 20, includes the details of now-canceled claims 27 and 28. New claim 52 is similar to claim 23 however the previous recitation of a precursor has been amended to recite a method. New claim 54 similarly has been revised as compared to now-canceled claim 25. No new matter has been added.

VIAL, H. et al. Appl. No. 10/031,486 October 25, 2004

The Section 112, second paragraph, rejection of claims 1-13 and 18-28 are believed to be obviated by the above amendments. The Examiner is requested to contact the undersigned if anything further is required in this regard. The claims are submitted to be definite.

The Section 112, first paragraph, rejection of claim 20 is moot in view of the above. New claim 49, which is similar to now-canceled claim 20, includes the recitation that the diseases to be treated are selected from malaria and babesiosis, which has been indicated by the Examiner as being supported by an enabling disclosure. The claims are submitted to be supported by an enabling disclosure and to be in condition for allowance.

A Notice of Allowance is requested and the Examiner is requested to contact the undersigned if anything further is required in this regard.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

. Sadoff Reg. No. 36,663

BJS:pp 1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100